← Back to Search

Senolytic Drug

Fisetin for Coronavirus (COVFIS-HOME Trial)

Phase 2

Waitlist Available

Led By James L Kirkland, MD, PhD

Research Sponsored by James L. Kirkland, MD, PhD

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 60 days

Awards & highlights

COVFIS-HOME Trial Summary

This trial will test whether the drug Fisetin can help reduce complications in people with COVID-19 infection.

Eligible Conditions

Coronavirus

COVFIS-HOME Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 60 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~60 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 60 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

World Health Organization (WHO) Ordinal Scale Score

Secondary outcome measures

Serious Adverse Events

Side effects data

From 2022 Phase 2 trial • 55 Patients • NCT04771611

Rash

hyperhidrosis

Chest pain

Diarrhea

Sinusitis

Infectious Rash

Back Pain

Headache

Worsening Headache

Dyspnea

sore throat

hypertension

tachycardia

amnesia

asthma with exacerbation

Anosmia

migraine

conjunctivitis

rhinitis

flu like symptoms

Otitis media

vertigo

edema, hand, bilateral

bacterial vaginosis

ear pain, left

cough

Upper Respiratory Infection

Epistaxis

flatulence

shortness of breath

arthoplasty

ageusia

change in smell

vomiting

fatigue

Colic Renal

Nephrolithiasis Calcium Oxalate

sneezing

thrush

right shoulder arthroscopy, rotator cuff, repair

watering eyes (epiphora)

Systolic murmur

100%

80%

60%

40%

20%

Study treatment Arm

Treatment Group

Placebo

COVFIS-HOME Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Treatment GroupExperimental Treatment1 Intervention

Subjects will receive treatment drug Fisetin

Group II: PlaceboPlacebo Group2 Interventions

Subjects will receive placebo

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Fisetin

2016

Completed Phase 2

~170

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

James L. Kirkland, MD, PhDLead Sponsor

1 Previous Clinical Trials

20 Total Patients Enrolled

James L Kirkland, MD, PhDPrincipal InvestigatorMayo Clinic

4 Previous Clinical Trials

310 Total Patients Enrolled

Avni Y. Joshi, MD, MSPrincipal InvestigatorMayo Clinic

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has Fisetin gone through the necessary channels for government approval?

"Fisetin is a Phase 2 clinical trial medication, meaning that while there is some evidence suggesting it is safe, there is no data yet supporting its efficacy."

Answered by AI

Is this the first time Fisetin has been trialed?

"There are currently seven different ongoing clinical trials studying Fisetin. Of these, none have reached Phase 3 and the majority of research is being conducted in Rochester, Minnesota."

Answered by AI

Are people still being signed up for this experiment?

"The clinical trial in question, which was initially posted on July 14th, 2021, is not currently seeking new participants. However, there are 1168 other trials that are recruiting patients."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications

James L. Kirkland, MD, PhD 2021. "COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04771611.